MedPath

Bausch Health Companies Inc

🇨🇦Canada
Ownership
-
Employees
20.2K
Market Cap
$2.1B
Website
Introduction

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

pharmaphorum.com
·

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

UCB's Bimzelx, approved in the EU for moderate to severe plaque psoriasis, challenges IL-17 inhibitors like Novartis' Cosentyx with superior efficacy in skin lesion clearance. UCB highlights Bimzelx's dual inhibition of IL-17A and IL-17F. Despite a crowded market, UCB remains confident, with Bimzelx pre-approved for NHS reimbursement and potential sales exceeding $2 billion annually.
pharmaphorum.com
·

FDA turns down Satsuma’s nasal migraine treatment

Satsuma Pharmaceuticals faces FDA approval delays for STS101, a dry powder intranasal migraine therapy, due to manufacturing issues. Competing with Impel Neuropharma's Trudhesa and Bausch Health's Migranal, STS101 aims to improve on Migranal's limitations. Despite setbacks, Satsuma plans to resubmit after addressing FDA concerns, without new clinical trials.
pharmaphorum.com
·

Aldeyra spies FDA filing ahead for dry eye drug reproxalap

Aldeyra Therapeutics is advancing with reproxalap for dry eye disease, despite mixed phase 3 trial results. After FDA discussions, it plans a US approval filing. Reproxalap showed rapid symptom improvement but faces competition from existing and emerging treatments like NOV03.
pharmaphorum.com
·

FDA Rejects UCB's Psoriasis Therapy Bimekizumab

The FDA declined to approve UCB's bimekizumab for psoriasis, citing unresolved inspection issues, impacting UCB's 2022 forecasts and stock. Despite approvals elsewhere and NICE's pre-approval in the UK, UCB faces stiff competition in the IL-17 inhibitor market, aiming to differentiate with its dual IL-17A and IL-17F inhibition. UCB hopes bimekizumab's potential in other indications can offset Cimzia's patent expiries.
menafn.com
·

Trichomoniasis Market Forecast 2032: FDA Approvals, Clinical Trials, Prevalence, Medication, Companies

The Trichomoniasis market is expected to grow significantly by 2032, driven by increased disease prevalence and new drug launches. Key players include Sekisui Diagnostics, Becton Dickinson, and Pfizer. Treatments like Secnidazole and Metronidazole are effective. The report covers market trends, epidemiology, and therapeutic advancements, emphasizing unmet needs and future opportunities.
springermedizin.de
·

Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.
openpr.com
·

Hepatic Encephalopathy Clinical Trials 2024: EMA, PDMA, FDA

DelveInsight's 'Hepatic Encephalopathy Pipeline Insight, 2024' report details the clinical development scenario and growth prospects for Hepatic Encephalopathy treatments, covering 3+ key companies and 3+ therapies in various stages of development, including Xifaxan, Golexanolone, and VE-303. The report provides insights into mechanism of action, route of administration, and market dynamics.
globenewswire.com
·

Allergy Relieving Eye Drops Market Global Forecast Report

The Allergy Relieving Eye Drops Market is projected to grow from USD 1.51 billion in 2023 to USD 2.37 billion by 2032, driven by rising allergy prevalence, demand for non-invasive solutions, and advancements in eye drop formulations. Key markets include Canada, France, India, and UAE, with major companies like AbbVie, Johnson & Johnson, and Pfizer leading the industry.
openpr.com
·

Anti-Aging Drugs Market Demand, Growth Prediction, Segments And Outlook By 2033

The anti-aging drugs market is projected to grow from $53.76 billion in 2023 to $77.85 billion in 2028, driven by aging populations, product innovations like SkinCeuticals' A.G.E Interrupter Advanced, and emerging technologies such as senolytic drugs and gene therapy.
insights.citeline.com
·

Skinny Label Limits: Supreme Court Denies Norwich Bid For US Xifaxan Reprieve

The US Supreme Court denied Norwich Pharmaceuticals' petition to review a case blocking its generic Xifaxan approval until 2029, despite removing the patent-protected indication from the label.
© Copyright 2025. All Rights Reserved by MedPath